Ge Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ge Li has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Angkhana Inta
Department of Biology, Faculty of Science, Chiang Mai University, Chiang Mai, Thailand
4 shared publications - Lixin Yang
Key Laboratory of Economic Plants and Biotechnology, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, China
4 shared publications - Chao Huang
School of Ethnic Medicine, Yunnan Minzu University, Kunming 650504, China
3 shared publications - Lu Gao
School of Ethnic Medicine, Yunnan Minzu University, Kunming 650504, China
3 shared publications - Terd Disayathanoowat
Department of Biology, Faculty of Science, Chiang Mai University
3 shared publications - Xiuxiang Yan
Key Laboratory of Economic Plants and Biotechnology, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, China
3 shared publications
Latest Publications
- Open Access
- 20 May 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (5) , 800
Core Substances and Related Bio-Activities on Anti-Lung Cancer Cell A549 of Pleione Pseudobulb
Background/Objectives: The Naxi people in Northwest Yunnan of China have used alcohol-soaked Pleione Pseudobulbus, which is the Pseudobulbus of Pleione bulbocodioides Rolfe (PBR), for lung diseases and tumors for a long period of time. This study aims to explore underlying mechanisms of bioactive ingredients in PBR, as well as to underscore the synergy between traditional medicine and modern pharmacological research. Methods: We verified the anti-tumor effects of the PBR extract through in vitro cell experiments, and explored its underlying mechanisms by combining untargeted metabolomics with network pharmacology to predict the related targets. Results: The anti-tumor potential of PBR extracts was systematically evaluated by integrating chemical profiling with in vitro cell-based assays. Untargeted metabolomics tentatively annotated metabolites spanning 12 major chemical classes, several of which have been previously reported to possess anti-tumor activity. To validate these annotations, prioritized candidates were further examined by LC-MS/MS against authentic reference standards at the nanogram scale, which confirmed the presence of sclareol—a naturally occurring diterpene with documented anti-tumor properties—as a constituent of PBR. Consistent with this chemical evidence, the PBR extract exerted multi-faceted anti-tumor effects in A549 lung cancer cells: it significantly suppressed proliferation, migration, and invasion; induced G0/G1-phase cell-cycle arrest; disrupted mitochondrial membrane potential; and modulated the expression of apoptosis-related proteins. Conclusions: By highlighting the pharmacological properties of cultivated PBR, we identified 118 overlapping targets between PBR compounds and lung disease-related targets, and we further selected 25 core lung cancer targets with high topological importance. This study suggests that the primary active compounds of Pleione bulbocodioides (Franch.) Rolfe may exert anti-lung cancer activity, potentially through targeting the EGFR tyrosine kinase inhibitor resistance pathway and the PI3K-Akt signaling pathway. Furthermore, in silico molecular docking suggested that the two major active compounds exhibited favorable predicted binding affinities with four core targets, particularly EGFR and AKT1, providing a basis for further experimental validation. These results support the potential value of Naxi traditional medicine and the need to further research onthese medicinal plants, thereby promoting Chinese herb medicine conservation efforts in the Naxi region.
- 20 May 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (5) , 800
Open AccessCore Substances and Related Bio-Activities on Anti-Lung Cancer Cell A549 of Pleione Pseudobulb
Background/Objectives: The Naxi people in Northwest Yunnan of China have used alcohol-soaked Pleione Pseudobulbus, which is the Pseudobulbus of Pleione bulbocodioides Rolfe (PBR), for lung diseases and tumors for a long period of time. This study aims to explore underlying mechanisms of bioactive ingredients in PBR, as well as to underscore the synergy between traditional medicine and modern pharmacological research. Methods: We verified the anti-tumor effects of the PBR extract through in vitro cell experiments, and explored its underlying mechanisms by combining untargeted metabolomics with network pharmacology to predict the related targets. Results: The anti-tumor potential of PBR extracts was systematically evaluated by integrating chemical profiling with in vitro cell-based assays. Untargeted metabolomics tentatively annotated metabolites spanning 12 major chemical classes, several of which have been previously reported to possess anti-tumor activity. To validate these annotations, prioritized candidates were further examined by LC-MS/MS against authentic reference standards at the nanogram scale, which confirmed the presence of sclareol—a naturally occurring diterpene with documented anti-tumor properties—as a constituent of PBR. Consistent with this chemical evidence, the PBR extract exerted multi-faceted anti-tumor effects in A549 lung cancer cells: it significantly suppressed proliferation, migration, and invasion; induced G0/G1-phase cell-cycle arrest; disrupted mitochondrial membrane potential; and modulated the expression of apoptosis-related proteins. Conclusions: By highlighting the pharmacological properties of cultivated PBR, we identified 118 overlapping targets between PBR compounds and lung disease-related targets, and we further selected 25 core lung cancer targets with high topological importance. This study suggests that the primary active compounds of Pleione bulbocodioides (Franch.) Rolfe may exert anti-lung cancer activity, potentially through targeting the EGFR tyrosine kinase inhibitor resistance pathway and the PI3K-Akt signaling pathway. Furthermore, in silico molecular docking suggested that the two major active compounds exhibited favorable predicted binding affinities with four core targets, particularly EGFR and AKT1, providing a basis for further experimental validation. These results support the potential value of Naxi traditional medicine and the need to further research onthese medicinal plants, thereby promoting Chinese herb medicine conservation efforts in the Naxi region.
- Open Access
- 30 May 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (6) , 823
Molecular Mechanisms of Panax japonicus var. major Against Gastric Cancer: Metabolite Analysis, Signaling Pathways, and Protein Targets
Background/Objectives: Ginseng (Panax japonicus var. major) is a traditional medicinal plant with anticancer properties. We aimed to assess the biological activity, potential targets, and molecular mechanisms of P. japonicus var. major in resisting gastric cancer. Methods: We developed a model that combines network pharmacology, molecular docking, untargeted metabolomics, and molecular dynamics simulations to predict which compounds from P. japonicus var. major might be active in the treatment of gastric cancer. We conducted in vitro experiments and immunoblot validation to test these predictions. Results: We identified 44 main active compounds from P. japonicus var. major and 29 core targets. These compounds showed anti-gastric cancer activity against the HGC-27 cell line by acting on TNF and T-cell receptor signaling pathways to diminish inflammatory factor production and promote apoptosis of gastric cancer cells. Clinical survival analysis identified four core proteins (CASP3, TNF, AKT1, and EGFR) whose abundance was associated with survival status in gastric cancer patients. Molecular docking, along with molecular dynamics simulations, revealed that these core proteins could be stably bound by the identified active compounds. The anti-gastric cancer effects of P. japonicus var. major compounds involved a lower Bcl-2/Bax ratio and upregulation of CASP3 and CASP9 levels, highlighting significant differences in anti-gastric cancer activity between extracts prepared from fresh versus dried P. japonicus var. major. Conclusions: Our results provide background for the indigenous medicinal use of P. japonicus var. major to treat gastric cancer and lay the foundation for further pharmacological experiments and clinical tests.
- 30 May 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (6) , 823
Open AccessMolecular Mechanisms of Panax japonicus var. major Against Gastric Cancer: Metabolite Analysis, Signaling Pathways, and Protein Targets
Background/Objectives: Ginseng (Panax japonicus var. major) is a traditional medicinal plant with anticancer properties. We aimed to assess the biological activity, potential targets, and molecular mechanisms of P. japonicus var. major in resisting gastric cancer. Methods: We developed a model that combines network pharmacology, molecular docking, untargeted metabolomics, and molecular dynamics simulations to predict which compounds from P. japonicus var. major might be active in the treatment of gastric cancer. We conducted in vitro experiments and immunoblot validation to test these predictions. Results: We identified 44 main active compounds from P. japonicus var. major and 29 core targets. These compounds showed anti-gastric cancer activity against the HGC-27 cell line by acting on TNF and T-cell receptor signaling pathways to diminish inflammatory factor production and promote apoptosis of gastric cancer cells. Clinical survival analysis identified four core proteins (CASP3, TNF, AKT1, and EGFR) whose abundance was associated with survival status in gastric cancer patients. Molecular docking, along with molecular dynamics simulations, revealed that these core proteins could be stably bound by the identified active compounds. The anti-gastric cancer effects of P. japonicus var. major compounds involved a lower Bcl-2/Bax ratio and upregulation of CASP3 and CASP9 levels, highlighting significant differences in anti-gastric cancer activity between extracts prepared from fresh versus dried P. japonicus var. major. Conclusions: Our results provide background for the indigenous medicinal use of P. japonicus var. major to treat gastric cancer and lay the foundation for further pharmacological experiments and clinical tests.
- Open Access
- 24 April 2025
- Published by MDPI AG in Preprints.org
Research on Anti-Gastric Cancer Activity of Panax japonicus var. major and Related Main Functional Compounds
Background/Objectives: Gastric cancer is a common malignant tumor worldwide, and few natural substances are available for its effective treatment. The ginseng Panax japonicus var. major is a natural medicinal plant with anticancer properties in terms of traditional knowledge of indigenous peoples in Yunnan of SW China. Methods: In this study, we employed network pharmacology, molecular docking, untargeted metabolomics and molecular dynamics simulations to predict the mode of action of active compounds from P. japonicus var. major in the treatment of gastric cancer. In vitro experiments and Western blot validation were conducted to validate these predictions. Results: Screened 44 main compounds which chikusetsu saponin IVa and calenduloside E inhibit the growth of gastric cancer cells) from P. japonicus var. major and explored 29 core decease targets which include four core targets (CASP3, TNF, AKT1, EGFR) of gastric cancer through two (TNF and T-cell receptor) signaling pathways. It is important that we not only found that the CASP3 and Chikusetsu saponin IVa formed a structurally stable complex with strong binding via multiple hydrogen bonds, but also revealed that both exert anti-gastric cancer effects by downregulating the Bcl-2/Bax ratio and upregulating the expression of CASP3 and CASP9 proteins, and provided the significant difference in anti-gastric cancer activity between two extracts from fresh and dried P. japonicus var. major. Conclusion: This results may provide a scientific supportting for indigenous medicine usage of P. japonicus var. major for gastric cancer treating and need further Pharmacological experiments and clinical experiments.
- 24 April 2025
- Published by MDPI AG in Preprints.org
Open AccessResearch on Anti-Gastric Cancer Activity of Panax japonicus var. major and Related Main Functional Compounds
Background/Objectives: Gastric cancer is a common malignant tumor worldwide, and few natural substances are available for its effective treatment. The ginseng Panax japonicus var. major is a natural medicinal plant with anticancer properties in terms of traditional knowledge of indigenous peoples in Yunnan of SW China. Methods: In this study, we employed network pharmacology, molecular docking, untargeted metabolomics and molecular dynamics simulations to predict the mode of action of active compounds from P. japonicus var. major in the treatment of gastric cancer. In vitro experiments and Western blot validation were conducted to validate these predictions. Results: Screened 44 main compounds which chikusetsu saponin IVa and calenduloside E inhibit the growth of gastric cancer cells) from P. japonicus var. major and explored 29 core decease targets which include four core targets (CASP3, TNF, AKT1, EGFR) of gastric cancer through two (TNF and T-cell receptor) signaling pathways. It is important that we not only found that the CASP3 and Chikusetsu saponin IVa formed a structurally stable complex with strong binding via multiple hydrogen bonds, but also revealed that both exert anti-gastric cancer effects by downregulating the Bcl-2/Bax ratio and upregulating the expression of CASP3 and CASP9 proteins, and provided the significant difference in anti-gastric cancer activity between two extracts from fresh and dried P. japonicus var. major. Conclusion: This results may provide a scientific supportting for indigenous medicine usage of P. japonicus var. major for gastric cancer treating and need further Pharmacological experiments and clinical experiments.
- Open Access
Ethnobotanical and Ethnopharmacological Study of Paris polyphylla var. yunnanensis in Yunnan Province, China
The traditional medicinal knowledge in the northwest of Yunnan Province, China have been poorly studied. Paris polyphylla var. yunnanensis (PPvY) is widely cultivated and used as indigenous traditional Chinese medicine (TCM) to treat cancer in northwest Yunnan. This study aims to reveal the traditional medicinal knowledge of PPvY and folk formulas related to PPvY through literature research and ethnobotanical investigation. Semi-structured interviews were conducted with 14 highly regarded folk doctors in the northwest of Yunnan, China, based on relevant data collected in the initial phase of the research. We identified twenty-three traditional treatments, thirty pairing herbs used with PPvY in therapy, and eight processing methods of PPvY. The results indicated that PPvY and its associated formulas containing PPvY were primarily used for treating cancer and inflammation and for clearing heat and detoxifying. The TCM herbs most frequently used alongside PPvY included Engleromyces sinensis and Glycyrrhiza yunnanensis. The commonly employed processing methods primarily involved using PPvY in both its dry and fresh forms, while special processing methods, such as processing in wine and honey, steaming, and foil-packet boiling, were worth further research. Our results highlight the diversity of medicinal plants and the richness of traditional medical knowledge in northwest Yunnan, China. This study may offer clues for the development and research of indigenous medicinal plants. Additionally, a collective effort is needed to create a plan for the sustainable use of indigenous medicinal plants, enhancing local economic development while safeguarding biodiversity and traditional medicinal knowledge.
Open AccessEthnobotanical and Ethnopharmacological Study of Paris polyphylla var. yunnanensis in Yunnan Province, China
The traditional medicinal knowledge in the northwest of Yunnan Province, China have been poorly studied. Paris polyphylla var. yunnanensis (PPvY) is widely cultivated and used as indigenous traditional Chinese medicine (TCM) to treat cancer in northwest Yunnan. This study aims to reveal the traditional medicinal knowledge of PPvY and folk formulas related to PPvY through literature research and ethnobotanical investigation. Semi-structured interviews were conducted with 14 highly regarded folk doctors in the northwest of Yunnan, China, based on relevant data collected in the initial phase of the research. We identified twenty-three traditional treatments, thirty pairing herbs used with PPvY in therapy, and eight processing methods of PPvY. The results indicated that PPvY and its associated formulas containing PPvY were primarily used for treating cancer and inflammation and for clearing heat and detoxifying. The TCM herbs most frequently used alongside PPvY included Engleromyces sinensis and Glycyrrhiza yunnanensis. The commonly employed processing methods primarily involved using PPvY in both its dry and fresh forms, while special processing methods, such as processing in wine and honey, steaming, and foil-packet boiling, were worth further research. Our results highlight the diversity of medicinal plants and the richness of traditional medical knowledge in northwest Yunnan, China. This study may offer clues for the development and research of indigenous medicinal plants. Additionally, a collective effort is needed to create a plan for the sustainable use of indigenous medicinal plants, enhancing local economic development while safeguarding biodiversity and traditional medicinal knowledge.